Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.
Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.


Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Friday, October 5, 2012

Federal Focus - October 2012

Congressional Agenda as Election Approaches In September, Congress passed and the President signed into law a Continuing Resolution that will keep the federal government and its programs operating for the next six months. This was necessary because Congress did not pass its twelve appropriations bills before the start of the fiscal year, October 1. As a result, priorities for the MS community such as funding for the National Institutes of Health (NIH) and MS research in the Congressionally Directed Medical Research Programs (CDMRP) are not likely to be determined for quite some time. Congress could finalize funding before the end of 2012 or wait until after the new Congress is sworn in next year. Their course will at least partly be determined by the outcome of the November elections. Weighing on Congress’s mind are the across-the-board cuts known as “sequestration” scheduled to take effect in early January 2013. Sequestration is required under the Budget Control Act because the Joint Select Committee on Deficit Reduction (the “Super Committee”) failed to reach a long-term compromise to reduce the federal deficit. The cuts will total $1.2 trillion in federal savings over the next ten years, with half of the cuts coming from defense spending and half from non-defense spending. Medicaid, Social Security, and Medicare beneficiaries are exempt from these cuts, but Medicare providers could face up to a 2% reduction each year. In mid-September, the Office of Management and Budget (OMB) released a report estimating the amount each federal agency would be cut. Under sequestration, many of the key healthcare agencies would be adversely affected. For example, OMB estimated that the NIH would face $2.52 billion in cuts and the Food and Drug Administration would lose $318 million. The Society joined over 3,000 national, state, and local organizations in a letter to Congress urging them to work with the President to avoid sequestration and protect non-defense discretionary programs that support important work like medical research and public health as much as possible. There is a small group of Senators talking and trying to reach a comprehensive and more specific deficit reduction that could delay sequestration, but consensus for now is far off and will also likely be impacted by the election. Medicare Prescription Drug Open Enrollment – Act by December 7 If you receive prescription drug coverage through Medicare Part D, now is the time to review your coverage choices and change to another plan-- if you need to. Medicare Part D’s Open Enrollment period begins on October 15th and ends on December 7th. This is the only time you can switch Medicare prescription drug plans during the calendar year unless you qualify for a special enrollment opportunity. Current enrollees should have received a notice from their plan if any changes are planned regarding the amount they will have to pay in premiums or out-of-pocket expenses or changes to the formulary (the list of medications the plan will cover). If you did not receive such a notice, you have the right to request it from your plan. To learn more about Medicare Part D in English or Spanish, see the official website. To speak with an MS Navigator, call us at 1-800-FIGHT-MS (1-800) 344-4867.

No comments:

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.